Olink Holding AB (OLK)
23.94
-0.01
(-0.04%)
USD |
NASDAQ |
May 17, 16:00
23.94
0.00 (0.00%)
After-Hours: 20:00
Olink Net Income (Quarterly): -16.06M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -16.06M |
| December 31, 2023 | -7.549M |
| September 30, 2023 | -1.819M |
| June 30, 2023 | -8.274M |
| March 31, 2023 | -13.96M |
| December 31, 2022 | 5.429M |
| September 30, 2022 | -1.288M |
| June 30, 2022 | -4.822M |
| March 31, 2022 | -12.17M |
| Date | Value |
|---|---|
| December 31, 2021 | -7.972M |
| September 30, 2021 | -5.471M |
| June 30, 2021 | -10.60M |
| March 31, 2021 | -14.30M |
| December 31, 2020 | 6.49M |
| September 30, 2020 | -0.105M |
| June 30, 2020 | -2.047M |
| March 31, 2020 | -11.12M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-16.06M
Minimum
Mar 2024
6.49M
Maximum
Dec 2020
-6.214M
Average
-7.549M
Median
Dec 2023
Net Income (Quarterly) Benchmarks
| Thermo Fisher Scientific Inc | 1.328B |
| Abliva AB | -2.377M |
| Karolinska Development AB | 0.0201M |
| Calliditas Therapeutics AB | -1.730M |
| Oncopeptides AB | -3.758M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 28.75M |
| Total Expenses (Quarterly) | 53.69M |
| EPS Diluted (Quarterly) | -0.13 |
| Enterprise Value | 2.869B |
| Gross Profit Margin (Quarterly) | 60.68% |
| Profit Margin (Quarterly) | -55.87% |
| Earnings Yield | -1.13% |
| Normalized Earnings Yield | -1.351 |